A2310 and A2311 Padiatrics Post-Hoc Safety Analysis Abstract

Plaque psoriasis affects adults and children. Secukinumab, a fully human monoclonal anti-interleukin-17A antibody, has proven efficacious in adults in the long-term treatment of multiple manifestations of psoriatic disease, with a favorable safety profile. Long-term pooled safety data for secukinumab in adult patients with moderate to severe plaque psoriasis have been reported earlier. Here, we report a pooled safety analysis from two phase 3 studies up to 52 weeks in pediatric patients with moderate to severe plaque psoriasis.